Corporate | 16 January 2013 07:00
|
Cytos Biotechnology AG / Key word(s): Research Update
Cytos provides update of Phase 2b clinical trial of CYT003 in allergic asthma Guidance for top-line results in 1H 2014 reiterated Schlieren (Zurich), Switzerland, January 16, 2013 – Cytos Biotechnology Ltd (SIX:CYTN) today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma. The clinical trial will recruit approximately 360 adult patients with moderate to severe allergic asthma not sufficiently controlled on current standard therapy. The study will be conducted at more than 90 centers in North America and Europe, and is expected to read out top-line data in 1H 2014. Regulatory approvals to conduct the trial have been obtained in various countries in Europe and North America including the United States, where an IND (Investigational New Drug) application has been approved by the US Food & Drug Administration. In the course of periodic drug quality measurements, a technical issue was identified with the rubber stoppers used to close the injection vials containing the clinical trial material. Cytos will replace this clinical trial material and have new material available at clinical trial sites in Q2 2013. Overall guidance for the clinical trial remains unchanged. Cytos expects to have top-line data available in the course of 1H 2014 and full data towards the end of 2014. Christian Itin, Chairman and CEO of Cytos Biotechnology, comments: 'We appreciate the support of our investigators and are looking forward to evaluating CYT003 in patients with allergic asthma.' ###
US Investor enquiries
About Cytos Biotechnology Ltd
This foregoing press release may contain forward-looking statements that include words or phrases such as 'are intended for', 'are designed to', or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. End of Corporate News 16.01.2013 This press release was distributed by EQS CORPORATE COMMUNICATIONS. www.eqs.com – news archive: www.eqs.com/ch/presskit The issuer is responsible for the contents of the release. |
| Language: | English | |
| Company: | Cytos Biotechnology AG | |
| Wagistr. 25 | ||
| 8952 Schlieren | ||
| Switzerland | ||
| Phone: | +41 44 733 4747 | |
| Fax: | +41 44 733 4740 | |
| E-mail: | info@cytos.com | |
| Internet: | www.cytos.com | |
| ISIN: | CH0011025217, CH0029060735 | |
| Swiss Security Number: | – | |
| Listed: | Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt; SIX | |
| End of News | EquityStory AG News-Service |
|
|
| 199166 16.01.2013 |